Supernus Pharmaceuticals filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company focused on central nervous system diseases. Recent Form 8-K reports cover operating results, conference-call related earnings releases, material definitive agreements, executive compensation arrangements, and other material events tied to the company's CNS product portfolio and corporate obligations.
Proxy materials describe annual meeting voting matters, director elections, advisory executive compensation votes, auditor ratification, and equity incentive plan amendments. The filings also identify the company's common stock structure, exchange listing, shareholder voting mechanics, governance practices, and capital-structure disclosures.
Form 144 Notice: The filing reports a proposed sale of 4,588 shares of common stock of Supernus Pharmaceuticals, Inc. (SUPN) through Morgan Stanley Smith Barney, with an aggregate market value of $205,909.44. The shares represent part of a holding originally acquired on 05/01/2012 as an in-kind distribution from NEA Partners.
The filer for whose account sales are reported is identified as Charles Newhall, who also sold 1,412 shares on 08/22/2025 for gross proceeds of $63,543.95. The issuer's total shares outstanding are listed as 56,073,088. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.
Supernus Pharmaceuticals (SUPN) filed a Form 144 notifying a proposed sale of 14,000 common shares. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ with an approximate aggregate market value of $623,070, representing part of the company's 56,073,088 shares outstanding. The filing shows the shares were acquired and will be sold on 08/25/2025 following an exercise of options under a registered plan and were paid for in cash on that date. The filer reports no securities sold in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Supernus Pharmaceuticals (SUPN) filed a Form 144 reporting a proposed sale of 1,412 shares of its common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $61,167.84 and the company reports 56,073,088 shares outstanding. The filing lists the acquisition of these shares as an in-kind distribution from NEA Partners on 11/16/2023, with the acquisition and payment dated 11/16/2023.
The filer indicates no securities sold in the past three months and includes standard representations about absence of undisclosed material adverse information. The notice appears to be a routine disclosure of an intended sale under Rule 144.
Form 144 filing for Supernus Pharmaceuticals, Inc. (SUPN) shows a proposed sale of 1,500 common shares to be executed on 08/22/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The shares were acquired the same day by exercise of stock options from the issuer and paid in cash. The filer discloses aggregated recent sales under 10b5-1 plans: three sales on 08/06/2025 totaling 140,000 shares with gross proceeds of $5,920,732.35 reported across three transactions. The notice includes the required representation that the seller is not aware of undisclosed material adverse information and references reliance on any 10b5-1 plan if applicable.
Supernus Pharmaceuticals (SUPN) notice of proposed sale reports an executive intends to sell 11,780 common shares via Morgan Stanley Smith Barney on 08/22/2025, with an aggregate market value of $524,133.43. The filing lists the acquisition history for the shares being sold: multiple restricted stock vestings between 2023 and 2025 and employee stock purchase plan purchases from 2022–2023, totaling the units specified. No sales by the same person in the prior three months are reported. The filer affirms no undisclosed material adverse information and includes the standard signature and certification language.
Insider sale by director under 10b5-1 plan. Bethany Sensenig, a director of Supernus Pharmaceuticals (SUPN), disposed of 5,369 shares of Common Stock on 08/14/2025 at a weighted average price of $42.25 per share. The sale was executed pursuant to a 10b5-1 trading plan adopted May 15, 2025. After the reported transactions the reporting person beneficially owned 0 shares. The Form 4 was filed with a signature executed by an attorney-in-fact on 08/18/2025. The filer committed to provide, upon request, details of the number of shares sold at each price within the $41.88 to $42.52 range.
Insider sale reported: Director Frederick M. Hudson sold 7,457 shares of Supernus Pharmaceuticals, Inc. (SUPN) on 08/14/2025 at a weighted-average price of $42.26 per share, with sale prices ranging from $42.14 to $42.37. After the transaction, Mr. Hudson beneficially owned 46,307 shares, reported as direct ownership. The Form 4 was signed on 08/18/2025 by an attorney-in-fact. The filing discloses only the non-derivative sale and provides an undertaking to supply detailed per-trade quantities and prices on request.
Armistice Capital, LLC and its managing member Steven Boyd filed an amended Schedule 13G reporting shared voting and dispositive power over 4,812,000 shares of Supernus Pharmaceuticals, Inc. (CUSIP 74346M406), equal to 8.58% of the outstanding common stock based on 56,073,088 shares outstanding as of July 29, 2025. The filing states the shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital acts as investment manager and exercises voting and investment power; the Master Fund disclaims beneficial ownership due to the Investment Management Agreement. The Reporting Persons certify the position was acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Supernus Pharmaceuticals (SUPN) filed a Form 144 disclosing a proposed sale of 7,457 common shares through Morgan Stanley Smith Barney LLC on the NASDAQ with an approximate aggregate market value of $315,116.41. The shares represent restricted stock that vested under a registered plan and were acquired from the issuer on 11/15/2023. The filing reports 56,073,088 shares outstanding for the issuer and indicates no securities sold by the reporting person in the past three months. The notice includes the standard signer representation that they are unaware of undisclosed material adverse information.
Insider transactions at Supernus Pharmaceuticals (SUPN): Sr. VP of IP and CSO Padmanabh P. Bhatt reported a net change in holdings tied to stock compensation and disposition activity. The reporting form shows a disposition of 13,049 shares of Common Stock and an acquisition of 1,250 performance share units (PSUs) that correspond to 1,250 underlying common shares, both reported with a transaction date of 08/07/2025. The 13,049-share figure includes 345 shares acquired through the company’s Employee Stock Purchase Plan. The PSUs were originally awarded on 02/23/2023 with performance objectives set on 06/12/2023, and a portion vested upon satisfaction of those objectives.